SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Array Biopharma, Inc
ARRY 8.660+3.2%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (284)8/21/2014 2:22:17 AM
From: tuck  Read Replies (2) of 321
 
Might be worth going over the partnership agreement. Not invested and currently busy, so not going to do it anytime soon myself. But have heard there is a non-compete clause in there that, even more than anti-trust issues, would compel NVS to return. This would probably not be redacted. Recent 2Q PR contains language suggesting ARRY expects return, but It could be just boilerplate.

If return happens and market kneejerks the stock price down, could be a good buying op.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News